Clinical Trials
10 trialsNCT07557914 2026-06-03
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT04539444 2026-06-02
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Completed
NCT06914011 2026-06-02
MRD2START
Asan Medical Center
Phase 3 Not yet recruiting
NCT07619937 2026-06-02
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Completed
NCT05542342 2026-06-01
SITISVEAL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT07136077 2026-06-01
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05211232 2026-05-29
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT07609121 2026-05-27
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07601737 2026-05-22
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT07413354 2026-05-12
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Tongji Hospital
Phase 2 Recruiting